Topobexin Targets a Unique Druggable Pocket of Topoisomerase II for Beta Isoform- Selective Control of DNA Damage During Anthracycline Chemotherapy
Jan Kubeš(University Hospital Hradec Králové), Matthew J. Schellenberg(Mayo Clinic), Anna Jirkovská(University Hospital Hradec Králové), Galina Karabanovich(University Hospital Hradec Králové), Taylor L. Witter(Mayo Clinic), Caroline A. Austin(Newcastle University), Iuliia Melnikova(University Hospital Hradec Králové), Veronika Keresteš(University Hospital Hradec Králové), Olga Lencova(University Hospital Hradec Králové), Anh Cong(Mayo Clinic in Arizona), Hana Bavlovic Piskackova(University Hospital Hradec Králové), Petra Štěrbová‐Kovaříková(University Hospital Hradec Králové), Tomáš Šimůnek(Charles University), Jaroslav Roh(Charles University), Martin Štěrba(Charles University), Lenka Applová(University Hospital Hradec Králové), Jasmina Paluncic, Jiřı́ Kuneš(University Hospital Hradec Králové), Julia R Alvey(Mayo Clinic in Arizona), Lise C. M. Arrouye(Mayo Clinic in Arizona), Petra Kollárová-Brázdová(University Hospital Hradec Králové)
Cited by 0
Related Papers
Human topoisomerases and their roles in genome stability and organization
|Nature Reviews Molecular Cell Biology|2022|446
Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology
|European Journal of Heart Failure|2020|344
Deficiency of terminal ADP‐ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease
|The EMBO Journal|2013|309